- Home
- CMRX
CMRX
Chimerix Inc.
as 12-18-2024 10:34am EST
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 77.1M | IPO Year: | 2013 |
| Target Price: | $8.50 | AVG Volume (30 days): | 11.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.75 - $3.39 | Next Earning Date: | 11-07-2024 |
| Revenue: | $159,000 | Revenue Growth: | -85.98% |
| Revenue Growth (this year): | -27.59% | Revenue Growth (next year): | 1690.28% |
Latest Chimerix Inc. News
CMRX Breaking Stock News: Dive into CMRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
3 Promising Penny Stocks With Market Caps Under $2B In US
MT Newswires
8 days ago
Sector Update: Health Care Stocks Decline Late Afternoon
GuruFocus.com
8 days ago
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy
MT Newswires
8 days ago
Chimerix Shares Soar Following Plans to Seek Accelerated Approval for Dordaviprone in Rare Brain Tumor
MT Newswires
8 days ago
Top Midday Gainers
Benzinga
8 days ago
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
GlobeNewswire
9 days ago
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
GlobeNewswire
12 days ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare CMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMRX Chimerix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.